Publications by authors named "Ma Luz Garcia Vivar"
Article Synopsis
- Rheumatoid arthritis (RA) is linked to changes in blood DNA methylation, and this study explores how these changes relate to the effectiveness of tumor necrosis factor inhibitor (TNFi) therapy.
- Researchers analyzed DNA methylation profiles in 62 RA patients before and after 12 weeks of TNFi treatment, identifying 139 biological functions influenced by the therapy that shifted toward healthy control patterns.
- The study found that the response to TNFi therapy is associated with specific methylation changes in immune cell types, indicating that the treatment helps restore normal blood methylation in RA patients.
Background: Blocking of the Tumor Necrosis Factor (TNF) activity is a successful therapeutic approach for 50-60% of rheumatoid arthritis (RA) patients. However, there are yet no biomarkers to stratify patients for anti-TNF therapy. Rheumatoid factor (RF) and anti-cyclic-citrullinated antibodies (anti-CCP) have been evaluated as biomarkers of response but the results have shown limited consistency.
View Article and Find Full Text PDFObjective: To compare the carotid intima-media thickness (IMT) assessed with automated radiofrequency-based US in RA patients treated with synthetic vs synthetic and biologic DMARDs and controls.
Methods: Ninety-four RA patients and 94 sex- and age-matched controls were prospectively recruited at seven centres. Cardiovascular (CV) risk factors and co-morbidities, RA characteristics and therapy were recorded.